• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Breaking barriers: patient-derived xenograft (PDX) models in lung cancer drug development-are we close to the finish line?

作者信息

Karim Nagla Abdel, Zaza Mohamed, Subramanian Janakiraman

机构信息

Department of Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA.

Department of Medicine, University of Virginia Medical Center, Charlottesville, VA, USA.

出版信息

Transl Lung Cancer Res. 2024 Aug 31;13(8):2098-2102. doi: 10.21037/tlcr-24-206. Epub 2024 Aug 19.

DOI:10.21037/tlcr-24-206
PMID:39263035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11384481/
Abstract
摘要

相似文献

1
Breaking barriers: patient-derived xenograft (PDX) models in lung cancer drug development-are we close to the finish line?突破障碍：肺癌药物研发中的患者来源异种移植（PDX）模型——我们接近终点了吗？
Transl Lung Cancer Res. 2024 Aug 31;13(8):2098-2102. doi: 10.21037/tlcr-24-206. Epub 2024 Aug 19.
2
MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.MET 抑制剂卡马替尼通过抑制非小细胞肺癌中的 MET/Akt/snail 信号通路和减少癌相关成纤维细胞的生成来克服奥希替尼耐药。
Aging (Albany NY). 2021 Feb 17;13(5):6890-6903. doi: 10.18632/aging.202547.
3
Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.非小细胞肺癌患者来源异种移植模型用于评估靶向药物敏感性和耐药性。
Cancer Sci. 2019 Oct;110(10):3215-3224. doi: 10.1111/cas.14171.
4
Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.奥希替尼耐药的 EGFR 驱动型肺癌 PDX 模型中 MET 通路激活的功能异质性。
Cancer Res Commun. 2024 Feb 8;4(2):337-348. doi: 10.1158/2767-9764.CRC-23-0321.
5
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).双重 MET 和 ERBB 抑制克服奥希替尼耐药晚期非小细胞肺癌（NSCLC）中的肿瘤内可塑性。
Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.
6
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.西妥昔单抗在肺腺癌患者来源的异种移植小鼠模型中抑制T790M介导的对表皮生长因子受体酪氨酸激酶抑制剂的耐药性。
Clin Lung Cancer. 2016 Sep;17(5):375-383.e2. doi: 10.1016/j.cllc.2016.01.002. Epub 2016 Jan 22.
7
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.卡马替尼（INC280）对非小细胞肺癌模型和其他具有明确 MET 激活机制的癌症类型具有活性。
Clin Cancer Res. 2019 May 15;25(10):3164-3175. doi: 10.1158/1078-0432.CCR-18-2814. Epub 2019 Jan 23.
8
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model.沙利度胺联合奥希替尼治疗 EGFR 突变阳性、MET 扩增的非小细胞肺癌模型的药代动力学/药效学分析。
Mol Cancer Ther. 2023 May 4;22(5):679-690. doi: 10.1158/1535-7163.MCT-22-0193.
9
Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With and -Driven Lung Cancer: Case Report.奥希替尼联合卡马替尼在一名伴有 和 驱动的肺癌患者中的颅内活性：病例报告
JTO Clin Res Rep. 2021 Mar 9;2(4):100162. doi: 10.1016/j.jtocrr.2021.100162. eCollection 2021 Apr.
10
Synchronous Double Primary Lung Adenocarcinomas With L858R Point Mutation and Exon 14 Skipping Mutation.伴有L858R点突变和外显子14跳跃突变的同步双原发性肺腺癌
J Med Cases. 2024 Aug;15(8):153-158. doi: 10.14740/jmc4210. Epub 2024 Jul 5.

引用本文的文献

1
Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer.用于肺癌抗肿瘤药物评估的由癌相关成纤维细胞和人脐静脉内皮细胞组成的3D-3共培养微珠的研制。
Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. doi: 10.21037/tlcr-2025-525. Epub 2025 Jun 26.

本文引用的文献

1
Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.奥希替尼对比含铂化疗用于 - 突变型晚期 NSCLC。
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
2
Patient-derived xenograft models in cancer therapy: technologies and applications.癌症治疗中的患者来源异种移植模型：技术与应用。
Signal Transduct Target Ther. 2023 Apr 12;8(1):160. doi: 10.1038/s41392-023-01419-2.
3
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model.
沙利度胺联合奥希替尼治疗 EGFR 突变阳性、MET 扩增的非小细胞肺癌模型的药代动力学/药效学分析。
Mol Cancer Ther. 2023 May 4;22(5):679-690. doi: 10.1158/1535-7163.MCT-22-0193.
4
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options.奥希替尼耐药：分子机制与新出现的治疗选择
Cancers (Basel). 2023 Jan 30;15(3):841. doi: 10.3390/cancers15030841.
5
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.辅助奥希替尼治疗 EGFR 突变型 IB-IIIA 期非小细胞肺癌：III 期随机 ADAURA 试验的更新结果。
J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31.
6
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.奥希替尼联合 savolitinib 克服表皮生长因子受体突变、MET 扩增的非小细胞肺癌获得性 MET 介导的耐药：TATTON。
Cancer Discov. 2023 Jan 9;13(1):98-113. doi: 10.1158/2159-8290.CD-22-0586.
7
Patient-derived xenograft (PDX) models, applications and challenges in cancer research.患者来源异种移植 (PDX) 模型在癌症研究中的应用及挑战。
J Transl Med. 2022 May 10;20(1):206. doi: 10.1186/s12967-022-03405-8.
8
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.对第三代表皮生长因子受体酪氨酸激酶抑制剂的获得性耐药以及新一代表皮生长因子受体抑制剂的出现。
Innovation (Camb). 2021 Apr 3;2(2):100103. doi: 10.1016/j.xinn.2021.100103. eCollection 2021 May 28.
9
Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer.卡马替尼治疗外显子 14 突变或扩增的非小细胞肺癌。
N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787.
10
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.塔顿：奥希替尼联合塞来替尼、索凡替尼或度伐鲁单抗治疗 EGFR 突变型肺癌的多臂 Ib 期试验。
Ann Oncol. 2020 Apr;31(4):507-516. doi: 10.1016/j.annonc.2020.01.013. Epub 2020 Jan 24.